AIMS: Abdominal aortic aneurysm (AAA) is characterized by extensive aortic wall matrix degradation that contributes to the remodelling and eventual rupture of the arterial wall. Elastinolytic cathepsin S (Cat S) is highly expressed in human aneurysmal lesions, but whether it contributes to the pathogenesis of AAA remains unknown. METHODS AND RESULTS: AAAs were induced in apolipoprotein E (ApoE) and Cat S compound mutant (Apoe(-/-)Ctss(-/-)) mice and in ApoE-deficient Cat S wild-type littermates (Apoe(-/-)Ctss(+/+)) by chronic angiotensin II infusion, and AAA lesions were analysed after 28 days. We found that Cat S expression increased significantly in mouse AAA lesions. The AAA incidence in Apoe(-/-)Ctss(-/-) mice was much lower than that in Apoe(-/-)Ctss(+/+) mice (10 vs. 80%). Cat S deficiency significantly reduced external and luminal abdominal aortic diameters, medial elastin fragmentation, and adventitia collagen content. Cat S deficiency reduced aortic lesion expression and the activity of matrix metalloproteinase (MMP)-2, MMP-9, and Cat K, but not the activity of other major cathepsins, such as Cat B and Cat L. Absence of Cat S significantly reduced AAA lesion media smooth muscle cell (SMC) apoptosis, lesion adventitia microvessel content, and inflammatory cell accumulation and proliferation. In vitro studies proved that Cat S helps promote SMC apoptosis, angiogenesis, monocyte and T-cell transmigration, and T-cell proliferation--all of which are essential to AAA pathogenesis. CONCLUSIONS: These data provide direct evidence that Cat S plays an important role in AAA formation and suggest that Cat S is a new therapeutic target for human AAA.
AIMS: Abdominal aortic aneurysm (AAA) is characterized by extensive aortic wall matrix degradation that contributes to the remodelling and eventual rupture of the arterial wall. Elastinolytic cathepsin S (Cat S) is highly expressed in humananeurysmal lesions, but whether it contributes to the pathogenesis of AAA remains unknown. METHODS AND RESULTS: AAAs were induced in apolipoprotein E (ApoE) and Cat S compound mutant (Apoe(-/-)Ctss(-/-)) mice and in ApoE-deficient Cat S wild-type littermates (Apoe(-/-)Ctss(+/+)) by chronic angiotensin II infusion, and AAA lesions were analysed after 28 days. We found that Cat S expression increased significantly in mouse AAA lesions. The AAA incidence in Apoe(-/-)Ctss(-/-) mice was much lower than that in Apoe(-/-)Ctss(+/+) mice (10 vs. 80%). Cat S deficiency significantly reduced external and luminal abdominal aortic diameters, medial elastin fragmentation, and adventitia collagen content. Cat S deficiency reduced aortic lesion expression and the activity of matrix metalloproteinase (MMP)-2, MMP-9, and Cat K, but not the activity of other major cathepsins, such as Cat B and Cat L. Absence of Cat S significantly reduced AAA lesion media smooth muscle cell (SMC) apoptosis, lesion adventitia microvessel content, and inflammatory cell accumulation and proliferation. In vitro studies proved that Cat S helps promote SMC apoptosis, angiogenesis, monocyte and T-cell transmigration, and T-cell proliferation--all of which are essential to AAA pathogenesis. CONCLUSIONS: These data provide direct evidence that Cat S plays an important role in AAA formation and suggest that Cat S is a new therapeutic target for human AAA.
Authors: F A Lederle; G R Johnson; S E Wilson; E P Chute; R J Hye; M S Makaroun; G W Barone; D Bandyk; G L Moneta; R G Makhoul Journal: Arch Intern Med Date: 2000-05-22
Authors: G P Shi; G K Sukhova; A Grubb; A Ducharme; L H Rhode; R T Lee; P M Ridker; P Libby; H A Chapman Journal: J Clin Invest Date: 1999-11 Impact factor: 14.808
Authors: R de Nooijer; I Bot; J H von der Thüsen; M A Leeuwenburgh; H S Overkleeft; A O Kraaijeveld; R Dorland; P J van Santbrink; S H van Heiningen; M M Westra; P T Kovanen; J W Jukema; E E van der Wall; Th J C van Berkel; G P Shi; E A L Biessen Journal: Arterioscler Thromb Vasc Biol Date: 2008-12-18 Impact factor: 8.311
Authors: Michal Abraham; Arnon Karni; Adi Dembinsky; Ariel Miller; Roopali Gandhi; David Anderson; Howard L Weiner Journal: J Autoimmun Date: 2008 Feb-Mar Impact factor: 7.094
Authors: Emilia Furmaniak-Kazmierczak; Scott W Crawley; Rhonda L Carter; Donald H Maurice; Graham P Côté Journal: Circ Res Date: 2007-04-19 Impact factor: 17.367
Authors: Jiusong Sun; Galina K Sukhova; Min Yang; Paul J Wolters; Lindsey A MacFarlane; Peter Libby; Chongxiu Sun; Yadong Zhang; Jian Liu; Terri L Ennis; Rebecca Knispel; Wanfen Xiong; Robert W Thompson; B Timothy Baxter; Guo-Ping Shi Journal: J Clin Invest Date: 2007-11 Impact factor: 14.808
Authors: Christopher D Payne; Mark A Deeg; Melanie Chan; Lai Hock Tan; Elizabeth Smith LaBell; Tong Shen; David J DeBrota Journal: Br J Clin Pharmacol Date: 2014-12 Impact factor: 4.335
Authors: Prabhakar K Jadhav; Matthew A Schiffler; Kostas Gavardinas; Euibong J Kim; Donald P Matthews; Michael A Staszak; D Scott Coffey; Bruce W Shaw; Kenneth C Cassidy; Richard A Brier; Yuke Zhang; Robert M Christie; William F Matter; Keyun Qing; Jim D Durbin; Yong Wang; Gary G Deng Journal: ACS Med Chem Lett Date: 2014-08-27 Impact factor: 4.345
Authors: Yi Zhou; Huimei Chen; Li Liu; Xueqing Yu; Galina K Sukhova; Min Yang; Vasileios C Kyttaris; Isaac E Stillman; Bruce Gelb; Peter Libby; George C Tsokos; Guo-Ping Shi Journal: J Immunol Date: 2017-01-16 Impact factor: 5.422
Authors: Mark J Osborn; Beau R Webber; Ronald T McElmurry; Kyle D Rudser; Anthony P DeFeo; Michael Muradian; Anna Petryk; Benedikt Hallgrimsson; Bruce R Blazar; Jakub Tolar; Elizabeth A Braunlin Journal: J Inherit Metab Dis Date: 2016-10-14 Impact factor: 4.982
Authors: Jose-Luiz Figueiredo; Masanori Aikawa; Chunyu Zheng; Jacob Aaron; Lilian Lax; Peter Libby; Jose Luiz de Lima Filho; Sabine Gruener; Jürgen Fingerle; Wolfgang Haap; Guido Hartmann; Elena Aikawa Journal: Am J Pathol Date: 2015-02-10 Impact factor: 4.307